ERBB2 and cancer: The role of the main two serum biomarkers troponin and natriuretic peptides in cancer patients receiving cardiotoxic cancer therapies (anthracycline chemotherapy, trastuzumab, HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy) was discussed extensively by a Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology [178].